Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial

Molecular Psychiatry

Volumn 21, Issue 8, 2016, Pages 1050-1056

  Yatham, L N ^a   Beaulieu, S ^b   Schaffer, A ^c   Kauer Sant'Anna, M ^d   Kapczinski, F ^d   Lafer, B ^e   Sharma, V ^f   Parikh, S V ^g   Daigneault, A ^h   Qian, H ⁱ   Bond, D J ^a   Silverstone, P H ^j   Walji, N ^a   Milev, R ^k   Baruch, P ^l   Da Cunha, A ^m   Quevedo, J ⁿ   Dias, R ^e   Kunz, M ^d   Young, L T ^c   Lam, R W ^a   Wong, H ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ ST PAUL S HOSPITAL   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

^k QUEEN S UNIVERSITY   (Canada)

^l CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^m Hospital Universitario de Santa Maria   (Brazil)

ⁿ UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; LITHIUM; OLANZAPINE; PLACEBO; PROLACTIN; RISPERIDONE; VALPROATE SEMISODIUM; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; TRANQUILIZER;

ADJUVANT THERAPY; ADULT; ARTICLE; BIPOLAR I DISORDER; BLOATING; COMMON COLD SYMPTOM; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRY SKIN; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FLATULENCE; GALACTORRHEA; HAIR LOSS; HEADACHE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MANIA; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE INJURY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; BIPOLAR DISORDER; MULTIMODALITY CANCER THERAPY; PROCEDURES; TIME FACTOR;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LITHIUM; MALE; RISPERIDONE; TIME FACTORS; WEIGHT GAIN;

EID: 84943655626     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.158     Document Type: Article

References (24)

1. Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry 2001; 62: 975-980.
2. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998; 59: 138-148.
3. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15: 1-44.
4. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388.
5. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-Term treatment of bipolar disorder. World J Biol Psychiatry 2013; 14: 154-219.
6. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263.
7. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488.
8. Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-Term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13: 133-144.
9. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130-137.
10. Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337-345.
11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 1994.
12. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
13. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-Treated patients. Acta Psychiatr Scand Suppl 1987; 33: 41-100.
17. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005; 76: 247-265.
18. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The longterm natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
19. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-Acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156-162.
20. Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-637.
21. Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012; 22: 339-346.
22. Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-Acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012; 22: 825-835.
23. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160: 112-117.
24. Wildes JE, Marcus MD, Fagiolini A. Obesity in patients with bipolar disorder: a biopsychosocial-behavioral model. J Clin Psychiatry 2006; 67: 904-915.